A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients with Uncontrolled Asthma.
12 Years - 75 Years
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Sept 2023 by AstraZeneca
No locations available
Benralizumab administered subcutaneously
Benralizumab subcutaneously on study week 0 until study week 40 inclusive.
|Placebo Comparator: Placebo|
Placebo administered subcutaneously
Placebo subcutaneously on study week 0 until study week 40 inclusive.